Erythroblastosis fetalis is a condition where a pregnant person’s immune system produces antibodies that cross the placenta and destroy the baby’s red blood cells. Also called hemolytic disease of the fetus and newborn (HDFN), it most commonly results from a mismatch between the mother’s and baby’s blood types, particularly the Rh factor. Thanks to modern prevention methods, Rh-related disease now occurs in only about 2.5 per 100,000 live births in developed countries, but when it does happen, it can cause severe anemia, organ damage, or stillbirth without treatment.
How Blood Type Mismatch Triggers the Condition
Red blood cells carry proteins on their surface called antigens. If the baby inherits an antigen from the father that the mother lacks, her immune system can recognize those fetal blood cells as foreign and mount an attack. The antibodies she produces are small enough to pass through the placenta, where they latch onto the baby’s red blood cells and mark them for destruction.
The most well-known trigger is Rh incompatibility. If the mother is Rh-negative and the baby is Rh-positive, small amounts of fetal blood entering the mother’s circulation during pregnancy or delivery can “sensitize” her immune system. This sensitization typically happens during a first pregnancy, so the first baby is usually unaffected. But in subsequent pregnancies with an Rh-positive baby, the mother’s immune system responds faster and more aggressively, producing large quantities of antibodies that can cause severe fetal anemia.
ABO incompatibility (for example, a mother with type O blood carrying a baby with type A or B) works differently. The mother already has naturally occurring antibodies against A and B antigens, so ABO-related disease can affect a first pregnancy. However, the immune response triggered by ABO antigens tends to be weaker. ABO incompatibility occurs in roughly 20% of births, but only about 1% of those newborns develop actual hemolytic disease, and when they do, it is generally milder than Rh disease.
What Happens to the Baby
When maternal antibodies destroy fetal red blood cells faster than the baby can replace them, several problems cascade. The most immediate is anemia. The baby’s bone marrow and liver work overtime to produce new red blood cells, releasing immature cells called erythroblasts into the bloodstream, which is where the condition gets its name.
Mild cases may cause only slight anemia and jaundice after birth. In moderate cases, the rapid breakdown of red blood cells floods the baby’s system with bilirubin, a yellow waste product. A newborn’s liver often cannot process bilirubin efficiently, leading to yellowing of the skin and eyes. If bilirubin levels climb high enough, the pigment can cross into brain tissue and cause a form of brain damage called kernicterus, which may result in hearing loss, movement disorders, or intellectual disability.
In the most severe cases, the baby develops hydrops fetalis, a life-threatening condition where massive fluid buildup occurs in the baby’s tissues and body cavities, including around the heart and lungs. The heart becomes overworked trying to compensate for the severe anemia, and without intervention, hydrops fetalis can lead to heart failure and stillbirth.
How It Is Detected
Screening starts early in pregnancy. A blood test identifies the mother’s blood type and Rh status, and an antibody screen checks whether she has already developed antibodies against fetal red blood cell antigens. If antibodies are found, their levels are monitored throughout the pregnancy to gauge how aggressively the immune system is responding.
To assess whether the baby is becoming anemic without resorting to invasive procedures, doctors use a specialized ultrasound that measures blood flow speed in an artery in the baby’s brain. When a baby is anemic, its blood becomes thinner and flows faster, so an increase in this measurement reliably signals that the baby’s red blood cell count is dropping. This technique has significantly reduced the need for riskier tests like amniocentesis or direct sampling of fetal blood.
After birth, two blood tests help confirm the diagnosis. One checks whether antibodies are already attached to the newborn’s red blood cells. The other screens the mother’s blood for unbound antibodies that could react with the baby’s cells. Together, these tests clarify whether the baby’s jaundice or anemia is being driven by maternal antibodies.
Treatment Before and After Birth
When ultrasound monitoring shows the baby is becoming significantly anemic while still in the womb, an intrauterine blood transfusion can be performed. A needle is guided through the mother’s abdomen into the umbilical cord, and compatible red blood cells are transfused directly into the baby’s circulation. In specialized centers, survival rates for babies who receive these transfusions exceed 90%. Some babies need multiple transfusions over several weeks before they are mature enough to deliver safely.
After birth, the primary concern is controlling bilirubin levels. Phototherapy, where the baby is placed under special blue-spectrum lights, is the first-line treatment. The light converts bilirubin in the skin into a form the baby can excrete without needing liver processing. For most affected newborns, phototherapy is sufficient.
If bilirubin rises dangerously high despite phototherapy, an exchange transfusion may be needed. In this procedure, small amounts of the baby’s blood are gradually removed and replaced with donor blood, physically washing out both the excess bilirubin and the circulating maternal antibodies. This is reserved for the most severe cases, typically when bilirubin levels approach or exceed 25 mg/dL or are climbing rapidly despite aggressive phototherapy.
Prevention With Rh Immune Globulin
The reason Rh disease has become rare is a preventive injection given to Rh-negative mothers. This injection contains antibodies that quickly clear any fetal Rh-positive blood cells from the mother’s system before her own immune system can detect them and form a lasting memory response.
The standard schedule includes one dose between weeks 26 and 28 of pregnancy and a second dose within 72 hours of delivering an Rh-positive baby. Additional doses are given after any event that might cause fetal blood to mix with the mother’s, such as miscarriage, ectopic pregnancy, abdominal trauma, or certain prenatal procedures. The timing matters: the injection must be given within 72 hours of exposure to be effective.
This prevention only works before sensitization occurs. Once a mother’s immune system has already learned to produce anti-Rh antibodies, the injection cannot undo that response. That is why consistent screening and timely administration during every pregnancy are critical. There is currently no equivalent preventive treatment for ABO incompatibility, but because ABO-related disease is almost always mild, prevention is less urgent.
Long-Term Outlook
Babies with mild disease who receive prompt phototherapy typically recover completely with no lasting effects. Those who needed intrauterine transfusions or exchange transfusions after birth generally do well, though they may need monitoring for anemia during the first few months of life as residual maternal antibodies continue to circulate and break down red blood cells. The baby’s own bone marrow gradually takes over, and the maternal antibodies naturally clear from the baby’s system, usually within two to three months.
The most significant long-term risks come from cases where bilirubin reached dangerously high levels before treatment. Kernicterus, once it occurs, causes permanent neurological damage. This outcome has become increasingly rare in settings with routine newborn screening and access to phototherapy, but it remains a risk when diagnosis or treatment is delayed.